The pooled results demonstrated that the addition of metformin could significantly improve the OS of diabetic NSCLC patients receiving EGFR-TKIs (HR = 0.64, 95% CI: 0.45–0.90, p = 0.011) (Table 2). Here, EGFR is linked to non-small cell lung carcinoma.